FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103320383> ?p ?o ?g. }

• W2103320383 abstract "Background and Purpose— Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recent studies have identified increased thromboembolic complications and/or mortality risks on EPO administration to patients with cancer or chronic kidney disease. Accordingly, the double-blind, placebo-controlled, randomized German Multicenter EPO Stroke Trial (Phase II/III; ClinicalTrials.gov Identifier: NCT00604630) was designed to evaluate efficacy and safety of EPO in stroke. Methods— This clinical trial enrolled 522 patients with acute ischemic stroke in the middle cerebral artery territory (intent-to-treat population) with 460 patients treated as planned (per-protocol population). Within 6 hours of symptom onset, at 24 and 48 hours, EPO was infused intravenously (40 000 IU each). Systemic thrombolysis with recombinant tissue plasminogen activator was allowed and stratified for. Results— Unexpectedly, a very high number of patients received recombinant tissue plasminogen activator (63.4%). On analysis of total intent-to-treat and per-protocol populations, neither primary outcome Barthel Index on Day 90 ( P =0.45) nor any of the other outcome parameters showed favorable effects of EPO. There was an overall death rate of 16.4% (n=42 of 256) in the EPO and 9.0% (n=24 of 266) in the placebo group (OR, 1.98; 95% CI, 1.16 to 3.38; P =0.01) without any particular mechanism of death unexpected after stroke. Conclusions— Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis." @default.
• W2103320383 created "2016-06-24" @default.
• W2103320383 creator A5000444230 @default.
• W2103320383 creator A5002871891 @default.
• W2103320383 creator A5006203982 @default.
• W2103320383 creator A5007750266 @default.
• W2103320383 creator A5009727911 @default.
• W2103320383 creator A5014629219 @default.
• W2103320383 creator A5015265189 @default.
• W2103320383 creator A5015908173 @default.
• W2103320383 creator A5016418059 @default.
• W2103320383 creator A5020087029 @default.
• W2103320383 creator A5021425597 @default.
• W2103320383 creator A5029033663 @default.
• W2103320383 creator A5030582121 @default.
• W2103320383 creator A5036198382 @default.
• W2103320383 creator A5049386810 @default.
• W2103320383 creator A5050550589 @default.
• W2103320383 creator A5055320315 @default.
• W2103320383 creator A5063837572 @default.
• W2103320383 creator A5068739017 @default.
• W2103320383 creator A5069268891 @default.
• W2103320383 creator A5077121195 @default.
• W2103320383 creator A5081553492 @default.
• W2103320383 date "2009-12-01" @default.
• W2103320383 modified "2023-10-13" @default.
• W2103320383 title "Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke" @default.
• W2103320383 cites W1924904321 @default.
• W2103320383 cites W1970916719 @default.
• W2103320383 cites W1979804841 @default.
• W2103320383 cites W1980957569 @default.
• W2103320383 cites W2005358912 @default.
• W2103320383 cites W2013177525 @default.
• W2103320383 cites W2040029744 @default.
• W2103320383 cites W2053166585 @default.
• W2103320383 cites W2059707463 @default.
• W2103320383 cites W2071155837 @default.
• W2103320383 cites W2077597832 @default.
• W2103320383 cites W2095473686 @default.
• W2103320383 cites W2096283301 @default.
• W2103320383 cites W2097396554 @default.
• W2103320383 cites W2122965222 @default.
• W2103320383 cites W2126715987 @default.
• W2103320383 cites W2136280619 @default.
• W2103320383 cites W2141132646 @default.
• W2103320383 cites W2142463112 @default.
• W2103320383 cites W2150250025 @default.
• W2103320383 cites W2157368934 @default.
• W2103320383 cites W2159233098 @default.
• W2103320383 cites W2164837040 @default.
• W2103320383 cites W2165323814 @default.
• W2103320383 cites W2168867226 @default.
• W2103320383 cites W2212003002 @default.
• W2103320383 cites W2292308933 @default.
• W2103320383 doi "https://doi.org/10.1161/strokeaha.109.564872" @default.
• W2103320383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19834012" @default.
• W2103320383 hasPublicationYear "2009" @default.
• W2103320383 type Work @default.
• W2103320383 sameAs 2103320383 @default.
• W2103320383 citedByCount "525" @default.
• W2103320383 countsByYear W21033203832012 @default.
• W2103320383 countsByYear W21033203832013 @default.
• W2103320383 countsByYear W21033203832014 @default.
• W2103320383 countsByYear W21033203832015 @default.
• W2103320383 countsByYear W21033203832016 @default.
• W2103320383 countsByYear W21033203832017 @default.
• W2103320383 countsByYear W21033203832018 @default.
• W2103320383 countsByYear W21033203832019 @default.
• W2103320383 countsByYear W21033203832020 @default.
• W2103320383 countsByYear W21033203832021 @default.
• W2103320383 countsByYear W21033203832022 @default.
• W2103320383 countsByYear W21033203832023 @default.
• W2103320383 crossrefType "journal-article" @default.
• W2103320383 hasAuthorship W2103320383A5000444230 @default.
• W2103320383 hasAuthorship W2103320383A5002871891 @default.
• W2103320383 hasAuthorship W2103320383A5006203982 @default.
• W2103320383 hasAuthorship W2103320383A5007750266 @default.
• W2103320383 hasAuthorship W2103320383A5009727911 @default.
• W2103320383 hasAuthorship W2103320383A5014629219 @default.
• W2103320383 hasAuthorship W2103320383A5015265189 @default.
• W2103320383 hasAuthorship W2103320383A5015908173 @default.
• W2103320383 hasAuthorship W2103320383A5016418059 @default.
• W2103320383 hasAuthorship W2103320383A5020087029 @default.
• W2103320383 hasAuthorship W2103320383A5021425597 @default.
• W2103320383 hasAuthorship W2103320383A5029033663 @default.
• W2103320383 hasAuthorship W2103320383A5030582121 @default.
• W2103320383 hasAuthorship W2103320383A5036198382 @default.
• W2103320383 hasAuthorship W2103320383A5049386810 @default.
• W2103320383 hasAuthorship W2103320383A5050550589 @default.
• W2103320383 hasAuthorship W2103320383A5055320315 @default.
• W2103320383 hasAuthorship W2103320383A5063837572 @default.
• W2103320383 hasAuthorship W2103320383A5068739017 @default.
• W2103320383 hasAuthorship W2103320383A5069268891 @default.
• W2103320383 hasAuthorship W2103320383A5077121195 @default.
• W2103320383 hasAuthorship W2103320383A5081553492 @default.
• W2103320383 hasBestOaLocation W21033203831 @default.
• W2103320383 hasConcept C126322002 @default.
• W2103320383 hasConcept C127413603 @default.
• W2103320383 hasConcept C141071460 @default.
• W2103320383 hasConcept C142724271 @default.

• next